GH56 Monotherapy for Second-line Treatment of MTAP-Deleted ESCC
A Multicenter, Open-Label Study to Evaluate Efficacy and Safety of GH56 Monotherapy for Second-line Treatment of Advanced Esophageal Squamous Cell Carcinoma With MTAP Deficiency
This is a Phase 2/3, open-label, multicenter study to evaluate the efficacy and safety of GH56 as a single agent in participants with advanced Esophageal Squamous Cell Carcinoma(ESCC) with methylthioadenosine phosphorylase (MTAP) deficiency in the second-line or later setting. In this seamlessly designed Phase 2/3 study, a single-arm Phase 2 study will be conducted first, and after favorable efficacy data are obtained, a Phase 3 study comparing against standard chemotherapy will then be conducted.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Bo Ning, Master
- Telefonnummer: +86-0512-86861608
- E-mail: ningbo@genhousebio.com
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Signed written informed consent, voluntarily participating in this study.
- Age ≥ 18 years, male or female.
- Patients with histopathologically or cytologically confirmed esophageal squamous cell carcinoma who cannot be treated surgically and have failed 1L standard of care (SoC) .
- MTAP deficiency is confirmed by IHC or NGS .
- At least one measurable lesion as per RECIST v1.1 criteria.
- ECOG performance status of 0 or 1.
- Life expectancy > 3 months.
- Adequate hematopoietic function, cardiac function, liver function, renal function, and coagulation function per local laboratory.
- Has a negative serum pregnancy test result at screening and is able to comply with contraceptive-barrier requirements.
Exclusion Criteria:
- Previous anti-tumor treatments did not meet the elution deadline requirements specified in the protocol; .
- Known or suspected that there is an allergy to GH56 active ingredients and/or GH56 capsule excipients;
- Prior treatment with an methionine adenosyltransferase 2α (MAT2A) inhibitor or a protein arginine methyltransferase 5 (PRMT5) inhibitor.
- Tumor invasion of the central nervous system, large blood vessels, trachea, serosal cavity, and other areas may have a significant impact on the compliance, safety, and efficacy evaluation of this trial .
- Patients cannot take oral medication or has severe absorption disorders .
- Unresolved toxicity from prior anti-cancer therapy.
- Patients with uncontrolled clinical symptoms or disease such as other malignant tumors, cardiovascular and cerebrovascular diseases, nervous/mental diseases, respiratory diseases, digestive diseases, immune and infectious diseases.
- Active infection of HIV, HBV, syphilis or HCV .
- Conditions that the investigator considers inappropriate for participation in this clinical trial.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: GH56 Capsule Group
GH56 RP2D administered to patients with MTAP-Deleted ESCC |
Planned dose administered on specified days per protocol |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (ORR)
Tidsramme: Approximately 2 years
|
The percentage of participants having complete response (CR) or partial response (PR) assessed based on RECIST V1.1 |
Approximately 2 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-Free Survival (PFS)
Tidsramme: Approximately 2 years
|
Progression-Free Survival assessed by investigators based RECIST v1.1 |
Approximately 2 years
|
|
Overall Survival (OS)
Tidsramme: Approximately 2 years
|
Overall Survival after first dose |
Approximately 2 years
|
|
Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE)
Tidsramme: Approximately 2 years
|
Adverse events (AEs) are defined as any untoward medical occurrence in clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests will be recorded as TEAEs |
Approximately 2 years
|
|
Pharmacokinetic characteristics of GH56
Tidsramme: Approximately 2 years
|
Plasma Concentration of GH56 |
Approximately 2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: bo Zheng Song, Doctorate, Zhejiang Cancer Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- GH56C204
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .